{
  "paper_metadata": {
    "pmid": "23776375",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted variants in the BRCA2 gene along with penetrance data and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.999del5",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "Icelandic population",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "A single BRCA2 mutation (999del5) has been found in the majority of multiple-case breast cancer families in the Icelandic population."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 999del5 mutation is associated with a high risk of breast cancer.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Accounts for about 8% of female breast cancer, rising to 24% of female breast cancers before the age of 40 years, and for about 38% of male breast cancers.",
      "evidence_level": "High",
      "source_location": "Results, paragraph 4",
      "additional_notes": "This variant is a founder mutation in the Icelandic population.",
      "key_quotes": [
        "A single BRCA2 mutation (999del5) has been found in the majority of multiple-case breast cancer families in the Icelandic population.",
        "The BRCA2 999del5 accounts for about 8% of female breast cancer, rising to 24% of female breast cancers before the age of 40 years, and for about 38% of male breast cancers."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.6174delT",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "Ashkenazi Jewish population",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "One in BRCA2 (6174delT) accounts for the majority of all BRCA1/2 mutations (>90%) in the Ashkenazi Jewish population."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 6174delT mutation is associated with a high risk of breast cancer.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Present in about 1% of Ashkenazi Jews and in 20% of Ashkenazi women affected by breast cancer before the age of 50 years.",
      "evidence_level": "High",
      "source_location": "Results, paragraph 4",
      "additional_notes": "This variant is a founder mutation in the Ashkenazi Jewish population.",
      "key_quotes": [
        "One in BRCA2 (6174delT) accounts for the majority of all BRCA1/2 mutations (>90%) in the Ashkenazi Jewish population.",
        "BRCA2 6174delT is present in about 1% of Ashkenazi Jews and in 20% of Ashkenazi women affected by breast cancer before the age of 50 years."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.372H",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 1,
        "demographics": "population-based study",
        "phenotype": "male breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "male breast cancer",
          "evidence_sentence": "Association between the BRCA2 N372H variant and increased breast cancer risk in particular has been reported from population-based studies."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 N372H variant is associated with an increased risk of male breast cancer.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Not specified.",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "This variant has been associated with male breast cancer risk.",
      "key_quotes": [
        "Association between the BRCA2 N372H variant and increased breast cancer risk in particular has been reported from population-based studies.",
        "We observed an association between the BRCA2 N372H variant and risk of male breast cancer in young patients."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant BRCA2 variants were extracted with detailed penetrance data."
  }
}